Comparative Pharmacology
Head-to-head clinical analysis: MIDOZALAM HYDROCHLORIDE versus SERAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIDOZALAM HYDROCHLORIDE versus SERAX.
MIDOZALAM HYDROCHLORIDE vs SERAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Midazolam hydrochloride is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion conductance, neuronal hyperpolarization, and inhibition of neuronal transmission. This produces sedative, anxiolytic, amnestic, and anticonvulsant effects.
SERAX (oxazepam) is a benzodiazepine that modulates GABA-A receptors, enhancing the inhibitory effect of GABA, leading to anxiolytic, sedative, and anticonvulsant effects.
2.5-10 mg IV bolus for induction; 0.05-0.2 mg/kg/h IV infusion for sedation. IM: 0.07-0.08 mg/kg (max 5 mg) 30-60 min pre-procedure.
Oral: 5-10 mg twice daily; maximum 20 mg/day. Intravenous: 2-5 mg slow IV push, may repeat after 2 hours.
None Documented
None Documented
Terminal elimination half-life: 1.5-3 hours in healthy adults; prolonged in elderly (up to 6 hours), obesity, hepatic cirrhosis (up to 20 hours), and congestive heart failure.
Terminal elimination half-life is 8-15 hours (mean 12 hours) in adults; prolonged in renal impairment.
Renal excretion of metabolites (approximately 90% as glucuronide conjugates, with less than 1% unchanged drug) and biliary/fecal excretion (approximately 5-10%).
Primarily renal (urinary) as unchanged drug (60-80%) and metabolites (20-40%); less than 5% fecal elimination.
Category C
Category C
Benzodiazepine
Benzodiazepine